Contact UsBiological Products
> Biopharmaceutical Industry Insight & News > Biological Products
| Product | Immuncell-LC | Company | Green Cross Cell Corp. |
|---|---|---|---|
| Classification | Cell Therapy product | Active Ingredient | Autologous activated T-cell |
| Reference Product | Approval Date | 2007 | |
| Indication | Liver cancer(hepatocellular carcinoma) | ||
| Description |
Immuncell-LC only uses immune cells of individual patients and can enhance patients' quality of life with virtually no pain or side effects.
Received approval for the hepatocellular carcinoma immunotherapy ‘Immuncell-LC’ from MFDS in 2007. Completed phase Ⅲ clinical trials for hepatocellular carcinoma and glioblastoma in korea. ① Adjuvant Immunotherapy With Autologous Cytokine-Induced Killer Cells for Hepatocellular Carcinoma(Gastroenterology, 2015) ② Phase III randomized trial of autologous cytokine-induced killer cell immunotherapy for newly diagnosed glioblastoma in korea(Oncotarget, 2016) ③ Phase II clinical trial of ex vivo‑expanded cytokine‑induced killer cells therapy in advanced pancreatic cancer(Cancer Immunology Immunotherapy, 2014) |
||
Korea Biomedicine Industry Association(KoBIA)
Address: 12, Teheran-ro 78-gil, Gangnam-gu, Seoul, Republic of Korea Tel: +82-2-725-8438 E-mail: info@kobia.kr
Address: 12, Teheran-ro 78-gil, Gangnam-gu, Seoul, Republic of Korea Tel: +82-2-725-8438 E-mail: info@kobia.kr
COPYRIGHT BY KoBIA. ALL RIGHTS RESERVED.